ArticleFrontiers in microbiology2021
Genomic Characterization of Carbapenem-Non-susceptible
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Prioritization of Critical Factors for Surveillance of the Dissemination of Antibiotic Resistance inInternational journal of molecular sciences · 2023Pooled it
- Aztreonam-avibactam at the frontline: A dual-agent approach to metallo-β-lactamase resistance.The Journal of antibiotics · 2026Review
- Increased Carbapenem resistance and gene carriage in Pseudomonas aeruginosa clinical isolates after the COVID-19 pandemic in Egypt.Molecular biology reports · 2026Article
- Global threats in local wards: Dissemination of high-risk clones resistant to last-generation cephalosporins and carbapenems in Iraqi hospitals.IJID regions · 2026Article
- High-risk lineages shape the resistome and virulome of multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Activity of cefiderocol againstMicrobiology spectrum · 2025Article
- Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Distinct relative abundances in pathogens detected in mechanically ventilated patients with suspected pneumonia in the intensive care unit at King Abdulaziz University Hospital.Scientific reports · 2025Article
- High-riskHeliyon · 2025Article
- Genomic analysis of prophages in 44 clinical strains ofFrontiers in cellular and infection microbiology · 2025Article
- A comprehensive review of the pathogenic mechanisms ofFrontiers in microbiology · 2025Review
- Molecular and clinical insights into extended-spectrum β-lactamase genes of Klebsiella pneumoniae isolated from neonatal sepsis in Ethiopia.BMC infectious diseases · 2024Article
- Global genomic epidemiology ofMicrobial genomics · 2024Article
- Genomic epidemiology and molecular characteristics of blaEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- High Prevalence of GES-5 Variant and Co-Expression of VIM-2 and GES-45 among ClinicalAntibiotics (Basel, Switzerland) · 2023Article
- Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.Antimicrobial agents and chemotherapy · 2023Article
- Epidemiological, Microbiological, and Clinical Characteristics of Multi-ResistantTropical medicine and infectious disease · 2023Article
- Prevalence of Carbapenem Non-susceptible Gram-Negative Bacteria at Tertiary Care Hospitals in Saudi Arabia.Cureus · 2023Article
- Evolving trends amongFrontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.